<bill session="117" type="h" number="7032" updated="2023-10-11T19:30:35Z">
  <state datetime="2022-03-09">REFERRED</state>
  <status>
    <introduced datetime="2022-03-09"/>
  </status>
  <introduced datetime="2022-03-09"/>
  <titles>
    <title type="display">Increasing Transparency in Generic Drug Applications Act of 2022</title>
    <title type="short" as="introduced">Increasing Transparency in Generic Drug Applications Act of 2022</title>
    <title type="official" as="introduced">To amend section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) with respect to a process to inform persons submitting an abbreviated application for a new drug whether the new drug is qualitatively or quantitatively the same as a listed drug, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="K000382"/>
  <cosponsors>
    <cosponsor bioguide_id="S001216" joined="2022-04-01"/>
  </cosponsors>
  <actions>
    <action datetime="2022-03-09">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-03-09" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-03-10">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="7667" relation="unknown"/>
    <bill session="117" type="s" number="4338" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2022-09-20T17:15:43Z" status="Introduced in House">Increasing Transparency in Generic Drug Applications Act of 2022

This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).</summary>
</bill>
